ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company
focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its
proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 7, 2017 at
4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2016 and recent operational
highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode
77596619. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at
www.regenxbio.com. The recorded webcast will be available for approximately 30 days following
the call.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant
adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery
platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s
mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and
commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and
third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in
the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 heather@argotpartners.com Media Laura Bagby, 312-448-8098 lbagby@6degreespr.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/7e7fa610-4f51-4de5-8405-434ddb99cd0c?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=MTg0IzY3MDM0Mjc=)